

Correction

Correction: Alarcia-Lacalle et al. Oritavancin Multiple Dosing for Complex Infections: A Pharmacokinetic/Pharmacodynamic Simulation Study. *Pharmaceutics* 2026, 18, 628

Ana Alarcia-Lacalle ¹, Miguel Ángel Morán-Rodríguez ^{2,3}, Laura Morata ⁴, Arantxa Isla ^{1,3},
Andrés Canut-Blasco ^{3,5} and Alicia Rodríguez-Gascón ^{1,3,*}

- ¹ Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Lascaray Research Centre, University of the Basque Country EHU, Paseo de la Universidad n° 7, 01006 Vitoria-Gasteiz, Spain; ana.alarcia@ehu.eus (A.A.-L.); arantxa.isla@ehu.eus (A.I.)
 - ² Infectious Disease Division, Araba University Hospital, Osakidetza Basque Health Service, Francisco Leandro de Viana Kalea, 01009 Vitoria-Gasteiz, Spain; miguelangel.moranrodriguez@osakidetza.eus
 - ³ Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, Bioaraba Health Research Institute, Jose Atxotegi Kalea s/n, 01009 Vitoria-Gasteiz, Spain; andres.canutblasco@osakidetza.eus
 - ⁴ Department of Infectious Diseases, Hospital Clínic of Barcelona, University of Barcelona, Carrer de Villarroel, 170, 08036 Barcelona, Spain; lmorata@clinic.cat
 - ⁵ Microbiology Service, Araba University Hospital, Osakidetza Basque Health Service, Francisco Leandro de Viana Kalea, 01009 Vitoria-Gasteiz, Spain
- * Correspondence: alicia.rodriguez@ehu.eus

Error in Figure

In the original published paper [1], there was a mistake in “Figure 1” as published. In Figure 1, some graphs were inadvertently mismatched with their descriptive subtitles; this mistake occurred during the assembly of the final figure from the individual graphs. The authors state that their scientific conclusions are unaffected. The corrected Figure 1 appears below. This correction was approved by the Academic Editor. The original publication has also been updated.



Received: 10 July 2026

Accepted: 13 July 2026

Published: 24 July 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.




Figure 1. Simulated oritavancin plasma concentration–time profiles for different dosage regimens. The blue line represents the median of the simulated oritavancin plasma concentrations, and the shaded area represents the simulation-based 95% confidence interval for the median. Horizontal dotted lines indicate the concentration values used for the estimation of PK/PD target attainment (concentration thresholds of 2 mg/L and 3 mg/L, and representative MIC values).

Reference

1. Alarcia-Lacalle, A.; Morán-Rodríguez, M.Á.; Morata, L.; Isla, A.; Canut-Blasco, A.; Rodríguez-Gascón, A. Oritavancin Multiple Dosing for Complex Infections: A Pharmacokinetic/Pharmacodynamic Simulation Study. *Pharmaceutics* **2026**, *18*, 628. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.